New Developments in Pharma Companies: $AZN $GSK $LLY

We have previously voiced concerns over the future of AstraZeneca (NYSE: AZN), in particular its lackluster pipeline (read more on high dividend pharma stocks). Based on the company’s situation, we anticipated that it would engage in M&A activity to bolster its pipeline. Yesterday’s announcement of AZN’s $1.3 billion acquisition of Ardea Biosciences falls in line with our speculation. The acquisition adds Phase III gout drug, lesinurad. Gout is prevalent in both developing and developed markets, but lesinurad is not expected to be a blockbuster drug given the cheapness and effectiveness of allopurinol. Peak sales estimates for the drug are less than a billion. We think this is just the beginning of AZN’s acquisition spree. It would make sense for AZN to build out its cardio, respiratory, and central nervous system portfolios since it already has existing products in those areas, but we would like to see the company make a concerted effort at enhancing its oncology franchise. So in short, Ardea will not be enough to save AZN, but additional tuck-in acquisitions to compensate for the upcoming Seroquel, Nexium, and Crestor expiries. This is a critical year for the company. If it does not succeed in building out its pipeline, the company will need to reevaluate its model and cost structure.

GlaxoSmithKline plc (ADR) (NYSE:GSK)

AZN is not the only big pharma with acquisition news, last week GlaxoSmithKline (NYSE: GSK), held by Warren Buffet, Christopher James, and Ken Fisher, made a $2.6 billion offer for Human Genome Sciences (NASDAQ: HGSI). GSK is already HGSI’s main partner and CEO Andrew Witty has reiterated what he sees as a logical fit saying, “We[GSK] absolutely believe that we are the compelling owner for this business…we have the rights and the operational control for the three main assets…” If the deal goes through, GSK would fully own Benlysta (lupus), which missed expected sales by a couple million this past quarter, darapladib (cardiovascular), and albiglutide (diabetes). Investors have been wondering if a “white knight” will come in, topping GSK’s bid; we do not think that is a likely scenario given the depth and breadth of the two companies’ partnership. The more likely outcome is that GSK may up its $13/share bid but not by much. Like AZN, GSK is also trying to recover from its patent cliff and dropping Avandia sales, but its pipeline is far more promising than AZN’s on the back of positive data for dabrafenib (BRAF inhibitor for melanoma) and lung cancer vaccine this past quarter. Q1 was a disappointing one, with revenue increasing a paltry 1% q-o-q, but we are optimistic on GSK’s prospects this year.

Competitor Eli Lilly (NYSE: LLY) also reported some news with a strong Q1 with EPS of $0.92 versus consensus estimates of $0.78. Robust Cymbalta sales, better-than-expected sales of Zyprexa (LLY’s antipsychotic drug), and resulting higher gross margins (78.6%) drove the earnings beat. Zyprexa generated $563 million in revenue while the street expected $488 million. Animal Health did very well with sales of $491 million and Straterra and Forteo revenues came in on the high side. Thus, management raised 2012 guidance from $3.10 to $3.20 in EPS to $3.15 to $3.30 on increased revenue contribution from Zyprexa. In terms of pipeline updates, solanezumab for Alzheimer’s will release data this summer and JAK 1/2 for rheumatoid arthritis has potential to begin Phase III trials this year based on data from the Phase IIb study should be released at the European League Against Rheumatism (EULAR) in June. Tasisulam, survivin ASO, and SARM/Cialis have been dropped from development. We are not concerned about the discontinuation of development for these products as they were not a huge focus or upcoming catalyst for the company.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Most Influential Papers In Economics

Top 8 Biggest Charities in the US

10 Worst Celebrity Career Moves Ever

Top 10 Best Paid Tennis Stars in the World

10 Cities with High Demand for Nurses

6 of the Worst Greeting Card Messages Ever Crafted

6 Ways to Make Money in ArcheAge and Build Your Empire

10 Foods To Eat To Lower Cholesterol Levels

The 10 Most Hated Television Characters of All Time

The 30 Worst Halloween Costume Ideas Ever Brought to Horrible Life

10 Vocational Skills in Demand Today with Jobs Waiting to be Filled

10 Best Places to Visit in Central and South America

The 10 Greatest Empires in History Which Nearly Conquered the World

The 6 Cheapest Boarding Schools In America 2015

5 Clear Reasons LoL is Better than DotA, Continues to Rule MOBAs

The Only 9 Teams with a Chance to Win the Super Bowl

The 15 Most Common Phobias in America that Induce Fits of Panic

Top 6 Least Expensive Tourist Destinations in 2014

Jim Goetz, Peter Fenton, Jim Breyer: Top 6 Venture Investors for 2014

Top 15 Billionaires in 2014

5 Pitfalls To Avoid When Buying a Franchise

Top 20 Medical Schools in the US – 2014 Rankings

4 Business Strategies that Turned Jamie Oliver into the World’s Richest Chef

6 Qualities That Make You A Good Team Player

10 High Paying Seasonal Jobs in America this Holiday Season

The 10 Busiest Shipping Lanes in the World

5 Most Valuable Brands in China

The 10 States with Highest Substance Abuse Rates Crippling Their Populace

The Top 10 Things to Do Before You Die That Will Echo for Eternity

The 10 Best Selling Items on Etsy

Top 10 Things to Do in Tokyo, the Greatest City in the World

10 Mistakes on Social Media that Can Harm You and Will Probably Get You Canned

The 10 Best Cities to Find Jobs in 2014

The 10 Most Controversial Songs Of All Time to Hit (and get Banned from) the Airwaves

The 20 Biggest IPOs in US History

The 10 Best Places to Visit in Mexico that Are Beautiful and Safe

7 Bad Habits that Age You Beyond Your Years

The 40 Best Fortune Cookie Sayings That Will Leave You Bemused, Befuddled, or Beguiled

10 Foods to Eat Before a Workout to Make Every Drop of Sweat Count

The 5 Best Documentaries On Netflix You Must See

The Most Heartwarming and Inspirational Story Of This Halloween Season, It Will Make You Cry and Jump For Joy

10 Best Party Songs of All Time to Bring the House Down With

5 New World Order Conspiracy Theories that Will Strangle the World

The 10 Highest Rated Movies of 2014

The 10 Largest Container Shipping Companies in the World

The 10 Largest Armies in the World: Who Should We Be Afraid Of?

Best Warren Buffett Quotes on Money You Need to Hear

The 10 Highest Suicide Rates by Profession

The 20 Most Underrated Movies of All Time

The 10 Fastest Growing Companies in America

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!